Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis
about
sameAs
The phosphatidylinositol 3-phosphate phosphatase myotubularin- related protein 6 (MTMR6) is a negative regulator of the Ca2+-activated K+ channel KCa3.1K+ channels as targets for specific immunomodulationThe intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humansPhosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cellsAlterations in reversible protein histidine phosphorylation as intracellular signals in cardiovascular diseasePotent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockersTRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activityNovel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3Adenylate cyclase 5 and KCa1.1 channel are required for EGFR up-regulation of PCNA in native contractile rat basilar artery smooth muscleKCa3.1 channels mediate the increase of cell migration and proliferation by advanced glycation endproducts in cultured rat vascular smooth muscle cellsThe smooth muscle cell-restricted KCNMB1 ion channel subunit is a direct transcriptional target of serum response factor and myocardin.Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries.Inhibition of the K+ channel K(Ca)3.1 reduces TGF-β1-induced premature senescence, myofibroblast phenotype transition and proliferation of mesangial cells.Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.Upregulation of intermediate-conductance Ca2+-activated K+ channels (KCNN4) in porcine coronary smooth muscle requires NADPH oxidase 5 (NOX5).Store-operated Ca(2+) entry is not essential for PDGF-BB induced phenotype modulation in rat aortic smooth musclePhosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1.Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.Nucleoside diphosphate kinase as protein histidine kinase.A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.Involvement of dominant-negative spliced variants of the intermediate conductance Ca2+-activated K+ channel, K(Ca)3.1, in immune function of lymphoid cellsThe Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosisHigh glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channelPhysiological epidermal growth factor concentrations activate high affinity receptors to elicit calcium oscillations.High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival.Modulation of K(Ca)3.1 channels by eicosanoids, omega-3 fatty acids, and molecular determinantsTungstate-targeting of BKαβ1 channels tunes ERK phosphorylation and cell proliferation in human vascular smooth muscle.The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.Calcium-activated potassium channel KCa3.1 in lung dendritic cell migrationMechanistic details of BK channel inhibition by the intermediate conductance, Ca2+-activated K channel.Endothelium-dependent nitric oxide and hyperpolarization-mediated venous relaxation pathways in rat inferior vena cava.The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders.Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease.Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's DiseaseInhibition of SK4 Potassium Channels Suppresses Cell Proliferation, Migration and the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells.Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore.
P2860
Q24300087-BB6D34A8-4CFB-4642-B8F3-D1E88A1D29A6Q24648323-356F1574-0744-4A4C-ABDC-CA383560AF62Q24648765-0B1A3135-17AC-4597-A78E-A8B138C7419DQ24671130-800831E0-9D70-4C35-93FD-99CAC81D9ADBQ26782883-5A1FF0F5-30C5-4FE1-8A9E-4B90431CD1A5Q28294590-A9CC3CEA-3B3D-4FF7-9BFA-9C1B82D37D0FQ28487726-FEA3CE99-5A7F-46E5-968D-33039B559C79Q28488052-3B7DC38C-3A18-4C8D-A07E-F85B66AF5F4EQ28570811-455CB655-34A7-4E86-B6FA-E54F27C71E19Q28573918-1ABD46D8-BA33-46A7-B255-2E16344237DEQ30434082-32CE5ACB-FC81-434F-BD83-2A39566791E3Q30440082-68660ABD-7476-43CB-BF24-EBA1565F017BQ30485571-582859FF-4F11-4D53-ABDC-873F319C6829Q31149306-FC6E1079-868B-4249-A7BF-7A0E1A3ECB75Q33654786-9C8AA89A-497A-44EC-81FA-CE19B77B78BEQ34075544-BA658143-3EDA-4AFB-A94E-C38FBF4BEBD6Q34088507-3B3D5BD5-1350-4AE5-B65A-1DC2E35DA635Q34298326-13310160-DBA3-4908-BB82-8AF2D817B789Q34403710-99539BAB-E8D7-4151-8506-D6283A67FE45Q34426352-AFBA6E07-1137-429C-A9A8-293A7D2E4409Q34946861-903ADC5B-79FD-4E74-A8CC-B7BBC9736885Q34947794-79026757-BD44-4419-A10A-E78F8319AEB7Q35060404-3ED42CC2-74CC-4550-95A6-C116F5F129A1Q35083097-BEF235B6-EF21-4BA0-95D9-FB2DBFE8FC0BQ35147905-B4BEC481-32A2-463C-9742-CD4D03EA9BDEQ35284559-D70B1DB2-82A0-4076-8DA7-B23F7D61444AQ35304761-533B0FCE-3475-4884-8F92-5202EE0A76F0Q35395940-6A810967-A04B-4956-ABC3-CE7142BC56F4Q35557265-5F88CD96-F304-4E50-B10E-049D688057C6Q35660234-8E7354D5-54DB-4BC8-B6B1-D9DB93552EF4Q35684871-47374839-F0B3-4D64-8AE1-34EDC7B8D890Q35797617-E9BFC4FA-B786-4551-A501-BD7D50718F50Q35873811-C3DCBAF0-936F-4936-8D01-97DD93AD89CEQ35880549-5FB0B1CA-DDA0-498A-BC4D-34BFAA528BAFQ35911129-F40F49DE-B2FA-41BB-A7BE-D931B4170188Q35915564-9BF13C3E-245F-4B21-998B-03F3D194225EQ35944615-D147DC19-FE90-4139-858C-F216E069E603Q35999547-2D3E14C9-DC12-40EF-9FCF-19969A465B54Q36001840-A2E3328D-3B33-45EE-8033-69AD2B7EE46EQ36261948-1B20E238-A31C-4573-A10D-55A1A896920B
P2860
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Blockade of the intermediate-c ...... peutic strategy for restenosis
@ast
Blockade of the intermediate-c ...... peutic strategy for restenosis
@en
Blockade of the intermediate-c ...... peutic strategy for restenosis
@nl
type
label
Blockade of the intermediate-c ...... peutic strategy for restenosis
@ast
Blockade of the intermediate-c ...... peutic strategy for restenosis
@en
Blockade of the intermediate-c ...... peutic strategy for restenosis
@nl
prefLabel
Blockade of the intermediate-c ...... peutic strategy for restenosis
@ast
Blockade of the intermediate-c ...... peutic strategy for restenosis
@en
Blockade of the intermediate-c ...... peutic strategy for restenosis
@nl
P2093
P3181
P1433
P1476
Blockade of the intermediate-c ...... peutic strategy for restenosis
@en
P2093
Andrea Knorr
Daniel Neumann
Doris Kämpfe
Hans-Dieter Orzechowski
Hans-Peter Reusch
Heike Wulff
Ines Eichler
Ivica Grgic
Joachim Hoyer
P304
P3181
P356
10.1161/01.CIR.0000086464.04719.DD
P407
P577
2003-09-02T00:00:00Z